Lv1
20 积分 2025-07-10 加入
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy
10天前
已完结
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
10天前
已完结
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies
17天前
已完结
Jurkat T cells and development of the T-cell receptor signalling paradigm
2个月前
已完结
Developing a Novel Enzalutamide‐Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells
3个月前
已完结
Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design
4个月前
已完结
Rapid Determination of the Specificity Constant of Irreversible Inhibitors (kinact/KI) by Means of an Endpoint Competition Assay
4个月前
已完结
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction
10个月前
已完结
皖公网安备34019202002308
